Primary resistance to osimertinib due to SCLC transformation: Issue of T790M determination on liquid re-biopsy.

@article{Minari2018PrimaryRT,
  title={Primary resistance to osimertinib due to SCLC transformation: Issue of T790M determination on liquid re-biopsy.},
  author={R Minari and Paola Bordi and Marzia Del Re and Francesco Facchinetti and Francesca Mazzoni and Fausto Barbieri and Andrea Camerini and Camila Eva Comin and Letizia Gnetti and Cinzia Azzoni and Rita Nizzoli and Beatrice Bortesi and Eleonora Rofi and Paolo Petreni and Nicoletta Campanini and Giulio Rossi and Romano Danesi and M Tiseo},
  journal={Lung cancer},
  year={2018},
  volume={115},
  pages={
          21-27
        }
}
OBJECTIVES EGFR T790M mutation is the most common mechanism of resistance to first-/second-generation EGFR tyrosine kinase inhibitors (TKIs) in non-small cell lung cancer (NSCLC) and could be overcome by third-generation EGFR-TKIs, such as osimertinib. Liquid biopsy, a non-invasive technique used to test the presence of the resistant mutation, may help avoiding tissue re-biopsy. However, analysing only circulating-free DNA, information about other less frequent and coexisting resistance… CONTINUE READING

Citations

Publications citing this paper.
SHOWING 1-10 OF 21 CITATIONS

Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer

Alessandro Leonetti, Sugandhi Sharma, +3 authors Marcello Tiseo
  • British Journal of Cancer
  • 2019
VIEW 9 EXCERPTS
CITES BACKGROUND
HIGHLY INFLUENCED

Concurrent Genetic Alterations Predict the Progression to Target Therapy in EGFR-Mutated Advanced NSCLC.

  • Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  • 2019
VIEW 1 EXCERPT
CITES BACKGROUND

Efficacy of osimertinib for the treatment of previously EGFR TKI treated NSCLC patients: a meta-analysis

Z.-X. Li, W. Zhao, +3 authors M.-S. Dong
  • Clinical and Translational Oncology
  • 2019
VIEW 1 EXCERPT
CITES BACKGROUND